menu ☰
menu ˟

VIDEO: Addition of ublituximab to ibrutinib effective for high-risk chronic lymphocytic leukemia

16 Jun 2017
CHICAGO — The addition of ublituximab to ibrutinib appeared safe and effective for patients with high-risk chronic lymphocytic leukemia, according to results from the phase 3 GENUINE study presented at the ASCO Annual Meeting. Kathryn S....

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.